Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,854,000 papers from all fields of science
Search
Sign In
Create Free Account
Cyclophosphamide
Known as:
CPM
, 2H-1,3,2-oxazaphosphorin-2-amine, N,N-is(2-chloroethyl)tetrahydro-,2-oxide
, N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Expand
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
47 relations
Narrower (16)
4-methylcyclophosphamide
ACP protocol
CEOP-B protocol
CHOP protocol-cyclophosphamide/doxorubicin/prednisone/vincristine
Expand
CEV regimen
CFP protocol
CMF-B protocol
CMFVP protocol
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
S. Viaud
,
F. Saccheri
,
+30 authors
L. Zitvogel
Science
2013
Corpus ID: 5012733
The Microbiota Makes for Good Therapy The gut microbiota has been implicated in the development of some cancers, such as…
Expand
Highly Cited
2010
Highly Cited
2010
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
J. Stone
,
P. Merkel
,
+26 authors
U. Specks
The New England journal of medicine
2010
Corpus ID: 7898433
BACKGROUND Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe…
Expand
Highly Cited
2006
Highly Cited
2006
Cyclophosphamide versus placebo in scleroderma lung disease.
D. Tashkin
,
R. Elashoff
,
+28 authors
M. Metersky
The New England journal of medicine
2006
Corpus ID: 22313529
BACKGROUND We conducted a double-blind, randomized, placebo-controlled trial to determine the effects of oral cyclophosphamide on…
Expand
Review
2005
Review
2005
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe
,
R. Abe
,
+332 authors
L. Martino
The Lancet
2005
Corpus ID: 7427749
Review
2005
Review
2005
Extended-Spectrum β-Lactamases: a Clinical Update
D. Paterson
,
R. Bonomo
Clinical Microbiology Reviews
2005
Corpus ID: 2035737
SUMMARY Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases which share the ability to hydrolyze…
Expand
Highly Cited
2001
Highly Cited
2001
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon
,
B. Leyland-Jones
,
+9 authors
L. Norton
The New England journal of medicine
2001
Corpus ID: 20066810
BACKGROUND The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30…
Expand
Review
1998
Review
1998
Polychemotherapy for early breast cancer: an overview of the randomised trials
M. Clarke
,
R. Collins
,
C. Davies
,
J. Godwin
,
R. Gray
,
R. Peto
The Lancet
1998
Corpus ID: 38457555
Highly Cited
1996
Highly Cited
1996
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
D. Alberts
,
P. Liu
,
+7 authors
B. Dubeshter
The New England journal of medicine
1996
Corpus ID: 26115122
BACKGROUND Intravenous platinum-based chemotherapy is the standard primary therapy for advanced ovarian cancer. We conducted a…
Expand
Highly Cited
1996
Highly Cited
1996
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W. Mcguire
,
W. Hoskins
,
+5 authors
M. Davidson
The New England journal of medicine
1996
Corpus ID: 23856250
BACKGROUND Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response…
Expand
Highly Cited
1947
Highly Cited
1947
DISEASE
1947
Corpus ID: 222064452
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE